Home > Insider Trading > Filing (0001225208-18-012883)

Filing Details

Accession Number:: 0001225208-18-012883
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-08-23 19:32:46
Reporting Period:: 2018-08-21

Accepted Time:: 2018-08-23 19:32:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1269021	Portola Pharmaceuticals Inc	PTLA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1250409	W Jeffrey Bird	755 Page Mill Road, Suite A-200 Palo Alto CA 94304-1005		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-08-21	137,563	$25.17	196,616	No	4	P	Indirect	By Trust (Trustees)
Common Stock	Acquisiton	2018-08-22	202,082	$26.09	398,698	No	4	P	Indirect	By Trust (Trustees)
Common Stock	Acquisiton	2018-08-23	50,355	$26.65	449,053	No	4	P	Indirect	By Trust (Trustees)

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Trust (Trustees)
No	4	P	Indirect	By Trust (Trustees)
No	4	P	Indirect	By Trust (Trustees)

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,000	Direct
Common Stock	45,402	Indirect	By Ltd Partnership (NEST)
Common Stock	921,610	Indirect	By Ltd Partnership (SHV)

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.89 to $26.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.41 to $26.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The reporting person shares pecuniary interest in these shares with other individuals pursuant to a contractual relationship. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in these shares.
Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
Shares held by Sutter Hill Ventures, a California Limited Partnership. The reporting person is a managing director and member of the management committee of the general partner of Sutter Hill Ventures, a California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.